FDAsafety guidance72% confidence
Medical Products for Rare Diseases and Conditions
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (immunology) as Boehringer Ingelheim.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Pulmonology · Lung Fibrosis
- Sub-indication
- Immunology
Related signal: Boehringer Ingelheim's Nerandomilast Trial for Lung Fibrosis in Autoimmune Diseases